QCI Asset Management Inc. NY Raises Stake in Regeneron Pharmaceuticals Inc (REGN)

QCI Asset Management Inc. NY lifted its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 1.5% in the 3rd quarter, HoldingsChannel reports. The fund owned 41,331 shares of the biopharmaceutical company’s stock after acquiring an additional 595 shares during the quarter. Regeneron Pharmaceuticals accounts for approximately 1.6% of QCI Asset Management Inc. NY’s investment portfolio, making the stock its 28th biggest position. QCI Asset Management Inc. NY’s holdings in Regeneron Pharmaceuticals were worth $16,699,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Founders Capital Management LLC bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth $226,000. Intl Fcstone Inc. bought a new position in Regeneron Pharmaceuticals in the second quarter valued at $233,000. Raymond James & Associates grew its position in Regeneron Pharmaceuticals by 57.4% in the second quarter. Raymond James & Associates now owns 81,916 shares of the biopharmaceutical company’s stock valued at $28,260,000 after purchasing an additional 29,864 shares in the last quarter. Signaturefd LLC grew its position in Regeneron Pharmaceuticals by 123.8% in the second quarter. Signaturefd LLC now owns 358 shares of the biopharmaceutical company’s stock valued at $124,000 after purchasing an additional 198 shares in the last quarter. Finally, First Trust Advisors LP grew its position in Regeneron Pharmaceuticals by 26.9% in the second quarter. First Trust Advisors LP now owns 187,988 shares of the biopharmaceutical company’s stock valued at $64,854,000 after purchasing an additional 39,879 shares in the last quarter. 66.06% of the stock is owned by institutional investors.

A number of research analysts recently weighed in on REGN shares. Canaccord Genuity reaffirmed a “$367.74” rating and issued a $304.00 target price on shares of Regeneron Pharmaceuticals in a research report on Thursday, July 19th. TheStreet raised shares of Regeneron Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Wednesday, July 25th. Argus raised their target price on shares of Regeneron Pharmaceuticals from $383.00 to $415.00 and gave the company a “buy” rating in a research report on Monday, July 16th. BidaskClub raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, September 1st. Finally, Morgan Stanley raised their target price on shares of Regeneron Pharmaceuticals from $370.00 to $396.00 and gave the company an “equal weight” rating in a research report on Friday, July 13th. Two research analysts have rated the stock with a sell rating, seventeen have given a hold rating and seven have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $410.95.

Shares of REGN stock opened at $356.66 on Friday. The firm has a market capitalization of $39.36 billion, a price-to-earnings ratio of 19.97, a PEG ratio of 1.22 and a beta of 1.34. The company has a quick ratio of 2.92, a current ratio of 4.04 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals Inc has a one year low of $281.89 and a one year high of $416.49.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, November 6th. The biopharmaceutical company reported $5.87 EPS for the quarter, beating analysts’ consensus estimates of $4.94 by $0.93. The firm had revenue of $1.66 billion during the quarter, compared to analysts’ expectations of $1.64 billion. Regeneron Pharmaceuticals had a net margin of 28.24% and a return on equity of 30.24%. The company’s revenue for the quarter was up 10.8% compared to the same quarter last year. During the same quarter last year, the company posted $3.99 earnings per share. As a group, equities research analysts predict that Regeneron Pharmaceuticals Inc will post 19.31 earnings per share for the current fiscal year.

In other Regeneron Pharmaceuticals news, major shareholder Sanofi sold 104,552 shares of the stock in a transaction on Thursday, September 6th. The shares were sold at an average price of $406.68, for a total value of $42,519,207.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Joseph L. Goldstein sold 2,000 shares of the stock in a transaction on Monday, September 24th. The shares were sold at an average price of $388.65, for a total transaction of $777,300.00. Following the completion of the sale, the director now owns 13,000 shares of the company’s stock, valued at approximately $5,052,450. The disclosure for this sale can be found here. In the last quarter, insiders sold 110,052 shares of company stock valued at $44,651,762. Corporate insiders own 12.42% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “QCI Asset Management Inc. NY Raises Stake in Regeneron Pharmaceuticals Inc (REGN)” was posted by Stock Observer and is the property of of Stock Observer. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.thestockobserver.com/2018/11/10/qci-asset-management-inc-ny-raises-stake-in-regeneron-pharmaceuticals-inc-regn.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

See Also: Technical Analysis of Stocks, How Can It Help

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply